LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
12.15
+0.33 (2.79%)
At close: Mar 13, 2026, 4:00 PM EDT
12.14
-0.01 (-0.08%)
After-hours: Mar 13, 2026, 6:51 PM EDT
LENZ Therapeutics Revenue
LENZ Therapeutics had revenue of $12.50M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $17.50M.
Revenue (ttm)
$17.50M
Revenue Growth
n/a
P/S Ratio
21.72
Revenue / Employee
$1,590,909
Employees
11
Market Cap
380.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 15.00M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLENZ News
- 5 days ago - LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia - GlobeNewsWire
- 20 days ago - LENZ Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Calamos Timpani Small Cap Growth Fund Q4 2025 Contributors And Detractors - Seeking Alpha
- 6 weeks ago - New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug - Benzinga
- 2 months ago - LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign - GlobeNewsWire
- 2 months ago - LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates - GlobeNewsWire
- 2 months ago - LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East - GlobeNewsWire
- 3 months ago - LENZ Therapeutics: Was That A Market Overreaction? - Seeking Alpha